A New Vision of IgA Nephropathy: The Missing Link
Fabio Sallustio(University of Bari Aldo Moro), Loreto Gesualdo(Unknown)
Cited by 52
Related Papers
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
|The Lancet|2023|264
The copy number variation landscape of congenital anomalies of the kidney and urinary tract
|Nature Genetics|2018|240
Genetic Drivers of Kidney Defects in the DiGeorge Syndrome
|New England Journal of Medicine|2017|154
Exome-wide Association Study Identifies GREB1L Mutations in Congenital Kidney Malformations
|The American Journal of Human Genetics|2017|106
Complement System and the Kidney: Its Role in Renal Diseases, Kidney Transplantation and Renal Cell Carcinoma
|International Journal of Molecular Sciences|2023|98